Infliximab for medical induction of remission in Crohn's disease

BACKGROUND: Infliximab is a monoclonal antibody that binds and neutralises tumour necrosis factor‐alpha (TNF‐α), which is present in high levels in the blood serum, mucosa and stool of people with Crohn's disease. OBJECTIVES: To evaluate the benefits and harms of infliximab alone or in combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Morris, Sinopoulou, Vassiliki, Akobeng, Anthony K, Radford, Shellie J, Eldragini, Mohsen, Darie, Ana-Maria, Moran, Gordon William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd 2023
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658649/
https://www.ncbi.nlm.nih.gov/pubmed/37982428
http://dx.doi.org/10.1002/14651858.CD012623.pub2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658649/
https://www.ncbi.nlm.nih.gov/pubmed/37982428
http://dx.doi.org/10.1002/14651858.CD012623.pub2

Ejemplares similares